Effect of Psychotropic Medications on Hammertoe Reconstruction Outcomes.
complications
depression
forefoot disorders
hammertoe
outcomes
psychiatry
psychotropic medications
Journal
Foot & ankle orthopaedics
ISSN: 2473-0114
Titre abrégé: Foot Ankle Orthop
Pays: United States
ID NLM: 101752333
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
entrez:
31
1
2022
pubmed:
25
8
2020
medline:
25
8
2020
Statut:
epublish
Résumé
Hammertoe deformities can seriously affect activity level and footwear. The use of prescription, mood-altering medications is very common, with some estimates as high as 25% of the population. Mood disorders, especially depression, negatively affect the results of medical and operative treatments. This study assessed the relationship of mood-altering medication use with the outcomes and complications of operative reconstruction of hammertoes. Data were prospectively collected from 116 patients who underwent hammertoe reconstruction, including demographic information, medical history, the use of mood-altering psychotropic medications (antidepressants, anxiolytics, hypnotics, and mood stabilizers), and postoperative complications. Preoperative patient-reported outcomes were measured using the visual analog scale (VAS) for pain and Short Form Health Survey (SF-36), which were repeated at 1-year follow-up. A total of 36.2% of patients were taking psychotropic medications. Medication and nonmedication groups had similar pain VAS and SF-36 Physical Component Summary (PCS) scores before and after surgery. Compared with nonmedication patients, patients on psychotropic medications had significantly lower SF-36 Mental Component Summary (MCS) scores preoperatively ( Patients taking psychotropic medications were equally likely to benefit from forefoot reconstruction as nonmedication patients. Preoperative and postoperative PCS and VAS were not significantly different between medication and nonmedication groups. Although the medication group had lower absolute MCS, they reported the same magnitude of improvement in MCS (ΔMCS) as the nonmedication group. Level II, prospective cohort study.
Sections du résumé
BACKGROUND
BACKGROUND
Hammertoe deformities can seriously affect activity level and footwear. The use of prescription, mood-altering medications is very common, with some estimates as high as 25% of the population. Mood disorders, especially depression, negatively affect the results of medical and operative treatments. This study assessed the relationship of mood-altering medication use with the outcomes and complications of operative reconstruction of hammertoes.
METHODS
METHODS
Data were prospectively collected from 116 patients who underwent hammertoe reconstruction, including demographic information, medical history, the use of mood-altering psychotropic medications (antidepressants, anxiolytics, hypnotics, and mood stabilizers), and postoperative complications. Preoperative patient-reported outcomes were measured using the visual analog scale (VAS) for pain and Short Form Health Survey (SF-36), which were repeated at 1-year follow-up.
RESULTS
RESULTS
A total of 36.2% of patients were taking psychotropic medications. Medication and nonmedication groups had similar pain VAS and SF-36 Physical Component Summary (PCS) scores before and after surgery. Compared with nonmedication patients, patients on psychotropic medications had significantly lower SF-36 Mental Component Summary (MCS) scores preoperatively (
CONCLUSIONS
CONCLUSIONS
Patients taking psychotropic medications were equally likely to benefit from forefoot reconstruction as nonmedication patients. Preoperative and postoperative PCS and VAS were not significantly different between medication and nonmedication groups. Although the medication group had lower absolute MCS, they reported the same magnitude of improvement in MCS (ΔMCS) as the nonmedication group.
LEVEL OF EVIDENCE
METHODS
Level II, prospective cohort study.
Identifiants
pubmed: 35097400
doi: 10.1177/2473011420944133
pii: 10.1177_2473011420944133
pmc: PMC8697102
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2473011420944133Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. ICMJE forms for all authors are available online.
Références
Foot Ankle Int. 2018 Apr;39(4):415-425
pubmed: 29337598
J Pharm Pract. 2012 Jun;25(3):368-73
pubmed: 22551560
Foot Ankle Int. 2010 May;31(5):372-6
pubmed: 20460062
NCHS Data Brief. 2017 Aug;(283):1-8
pubmed: 29155679
Foot Ankle Int. 2018 Jun;39(6):681-688
pubmed: 29444584
Foot Ankle Int. 2014 Nov;35(11):1103-7
pubmed: 25301891
JAMA. 2003 Jul 9;290(2):215-21
pubmed: 12851276
Instr Course Lect. 2003;52:421-44
pubmed: 12690869
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
BMC Health Serv Res. 2008 May 22;8:108
pubmed: 18498638
Foot Ankle Int. 2005 Apr;26(4):320-5
pubmed: 15829216
Foot Ankle Int. 2014 Apr;35(4):319-25
pubmed: 24443491
J Alzheimers Dis. 2005 Sep;8(1):43-50
pubmed: 16155348
J Bone Joint Surg Am. 2009 Aug;91(8):2014-8
pubmed: 19651964
Foot Ankle Int. 2000 Feb;21(2):94-104
pubmed: 10694020
Foot Ankle Int. 2018 Jul;39(7):795-800
pubmed: 29620945
Foot Ankle Int. 2006 May;27(5):383-90
pubmed: 16701063
J Hand Microsurg. 2010 Jun;2(1):18-23
pubmed: 23129948
J Shoulder Elbow Surg. 2014 Apr;23(4):519-27
pubmed: 24630546
J Cardiovasc Nurs. 2013 Sep-Oct;28(5):429-43
pubmed: 22728774
Foot Ankle Spec. 2014 Jun;7(3):185-92
pubmed: 24756117
J Bone Joint Surg Am. 2006 Sep;88(9):1983-8
pubmed: 16951115
BMC Health Serv Res. 2012 Jun 19;12:166
pubmed: 22713232
Foot Ankle Clin. 2011 Dec;16(4):573-82
pubmed: 22118230
Psychiatr Q. 2006 Fall;77(3):203-9
pubmed: 16958003
Dan Med J. 2012 Dec;59(12):B4560
pubmed: 23290295
Foot Ankle Int. 2017 Nov;38(11):1192-1198
pubmed: 28814108
Foot Ankle Int. 2015 May;36(5):494-502
pubmed: 25677363
J Foot Ankle Surg. 2012 Nov-Dec;51(6):711-3
pubmed: 22884907
Annu Rev Public Health. 2012 Apr;33:123-35
pubmed: 22429161
Gen Hosp Psychiatry. 2014 Sep-Oct;36(5):523-7
pubmed: 24973124